Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges

REFERENCES

• Yu SY, Zhu YJ, and Li WG: Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res 56, 117–124, 1997.
   PubMed Web of Science ®Google Scholar
• Yu SY, Li WG, Zhu YJ, Yu WP, and Hou C: Chemoprevention trial of human hepatitis with selenium supplementation in China. Biol Trace Elem Res 20, 15–22, 1989.
   PubMed Web of Science ®Google Scholar
• Clark LC, Combs GF, Jr., Turnbull BW, Slate EH, Chalker DK, et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957–1963, 1996.
   Google Scholar
• Clark LC, Dalkin B, Krongrad A, Combs GF, Jr., Turnbull BW, et al.: Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 81, 730–734, 1998.
   PubMedGoogle Scholar
• Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Jr., Slate EH, et al.: Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11, 630–639, 2002.
   PubMed Web of Science ®Google Scholar
• Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, et al.: Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91, 608–612, 2003.
   PubMed Web of Science ®Google Scholar
• Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Jr., et al.: Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97, 94–102, 2005.
   PubMed Web of Science ®Google Scholar
• Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al.: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39–51, 2009.
   PubMed Web of Science ®Google Scholar
• Marshall JR, Tangen CM, Sakr WA, Wood DP, Jr., Berry DL, et al.: Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-Grade Prostatic Intraepithelial Neoplasia: SWOG S9917. Cancer Prev Res (Phila) 4, 1761–1769, 2011.
   PubMed Web of Science ®Google Scholar
• Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, et al.: Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate 73, 328–335, 2013.
   PubMed Web of Science ®Google Scholar
• Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, et al.: Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol 31, 4179–4187, 2013.
   PubMed Web of Science ®Google Scholar
• Klein EA, Thompson IM, Jr., Tangen CM, Crowley JJ, Lucia MS, et al.: Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306, 1549–1556, 2011.
   PubMed Web of Science ®Google Scholar
• Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, et al.: Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst 106, djt456, 2014.
   PubMed Web of Science ®Google Scholar
• Virtamo J, Pietinen P, Huttunen JK, Korhonen P, Malila N, et al.: Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 290, 476–485, 2003.
   PubMed Web of Science ®Google Scholar
• Potter JD: The failure of cancer chemoprevention. Carcinogenesis 35, 974–982, 2014.
   PubMed Web of Science ®Google Scholar
• Lu J and Jiang C: Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid Redox Signal 7, 1715–1727, 2005.
   PubMed Web of Science ®Google Scholar
• Ip C: Lessons from basic research in selenium and cancer prevention. J Nutr 128, 1845–1854, 1998.
   PubMed Web of Science ®Google Scholar
• Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, et al.: Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila) 2, 484–495, 2009.
   PubMed Web of Science ®Google Scholar
• El-Bayoumy K: The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis. Nutr Cancer 61, 285–286, 2009.
   PubMed Web of Science ®Google Scholar
• Hatfield DL and Gladyshev VN: The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. Mol Interv 9, 18–21, 2009.
   PubMed Web of Science ®Google Scholar
• Christensen MJ: Selenium and prostate cancer prevention: what next-if anything? Cancer Prev Res (Phila) 7, 781–785, 2014.
   PubMed Web of Science ®Google Scholar
• Lu J, Jiang C, and Zhang J, Cancer Prevention with Selenium: costly lessons and difficult but bright future prospects. In: Inflammation, Oxidative Stress and Cancer, A.-N.T. Kong (ed.). CRC Press Taylor & Francis, Boca Raton, FL, 2014, pp. 477–494.
   Google Scholar
• Neve J: Human selenium supplementation as assessed by changes in blood selenium concentration and glutathione peroxidase activity. J Trace Elem Med Biol 9, 65–73, 1995.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (U.S.), Panel on Dietary Antioxidants and Related Compounds. Dietary references intakes for vitamin C, vitamin E, selenium and carotenoids 2000, Washington DC: National Academy Press. 284–324.
   Google Scholar
• Xia Y, Hill KE, Li P, Xu J, Zhou D, et al.: Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects. Am J Clin Nutr 92, 525–531, 2010.
   PubMed Web of Science ®Google Scholar
• Ervin RB, Wang CY, Wright JD, and Kennedy-Stephenson J: Dietary intake of selected minerals for the United States population: 1999–2000. Adv Data, 1–5, 2004.
   Google Scholar
• Ford ES, Mokdad AH, Giles WH, and Brown DW: The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 52, 2346–2352, 2003.
   PubMed Web of Science ®Google Scholar
• Niskar AS, Paschal DC, Kieszak SM, Flegal KM, Bowman B, et al.: Serum selenium levels in the US population: Third National Health and Nutrition Examination Survey, 1988–1994. Biol Trace Elem Res 91, 1–10, 2003.
   PubMed Web of Science ®Google Scholar
• Combs GF, Jr., Clark LC, and Turnbull BW: An analysis of cancer prevention by selenium. Biofactors 14, 153–159, 2001.
   PubMed Web of Science ®Google Scholar
• Combs GF, Jr., Watts JC, Jackson MI, Johnson LK, Zeng H, et al.: Determinants of selenium status in healthy adults. Nutr J 10, 75, 2011.
   PubMed Web of Science ®Google Scholar
• Richie JP, Jr., Das A, Calcagnotto AM, Sinha R, Neidig W, et al.: Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: a randomized clinical trial. Cancer Prev Res (Phila) 7, 796–804, 2014.
   PubMed Web of Science ®Google Scholar
• Redman C, Xu MJ, Peng YM, Scott JA, Payne C, et al.: Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis 18, 1195–1202, 1997.
   PubMed Web of Science ®Google Scholar
• Menter DG, Sabichi AL, and Lippman SM: Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9, 1171–1182, 2000.
   PubMed Web of Science ®Google Scholar
• Chigbrow M and Nelson M: Inhibition of mitotic cyclin B and cdc2 kinase activity by selenomethionine in synchronized colon cancer cells. Anticancer Drugs 12, 43–50, 2001.
   PubMed Web of Science ®Google Scholar
• Goel A, Fuerst F, Hotchkiss E, and Boland CR: Selenomethionine induces p53 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cancer Biol Ther 5, 529–535, 2006.
   PubMed Web of Science ®Google Scholar
• Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, et al.: A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. Clin Cancer Res 12, 1237–1244, 2006.
   PubMed Web of Science ®Google Scholar
• Combs GF, Jr., Jackson MI, Watts JC, Johnson LK, Zeng H, et al.: Differential responses to selenomethionine supplementation by sex and genotype in healthy adults. Br J Nutr 107, 1514–1525, 2012.
   PubMed Web of Science ®Google Scholar
• McCormick DL, Rao KV, Johnson WD, Bosland MC, Lubet RA, et al.: Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate. Cancer Prev Res (Phila) 3, 381–392, 2010.
   PubMed Web of Science ®Google Scholar
• Ozten N, Horton L, Lasano S, and Bosland MC: Selenomethionine and alpha-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model. Cancer Prev Res (Phila) 3, 371–380, 2010.
   PubMed Web of Science ®Google Scholar
• Ozten N, Schlicht M, Diamond AM, and Bosland MC: L-selenomethionine does not protect against testosterone plus 17beta-estradiol-induced oxidative stress and preneoplastic lesions in the prostate of NBL rats. Nutr Cancer 66, 825–834, 2014.
   PubMed Web of Science ®Google Scholar
• Corcoran NM, Najdovska M, and Costello AJ: Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 171, 907–910, 2004.
   PubMed Web of Science ®Google Scholar
• Li GX, Lee HJ, Wang Z, Hu H, Liao JD, et al.: Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 29, 1005–1012, 2008.
   PubMed Web of Science ®Google Scholar
• Yan L and Demars LC: Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice. Int J Cancer, 2011.
   Web of Science ®Google Scholar
• Combs GF, Jr. and Gray WP: Chemopreventive agents: selenium. Pharmacol Ther 79, 179–192, 1998.
   PubMed Web of Science ®Google Scholar
• Lu J, Hu H, and Jiang C, Regulation of signaling pathways by selenium in cancer. In Dietary Modulation of Cell Signaling Pathways, Surh Z, Cadenas E., and Packer L (eds.). CRC Press, Boca Raton, FL, 2009, p. 42.
   Google Scholar
• Ip C, Dong Y, and Ganther HE: New concepts in selenium chemoprevention. Cancer Metastasis Rev 21, 281–289, 2002.
   PubMed Web of Science ®Google Scholar
• Hatfield DL, Tsuji PA, Carlson BA, and Gladyshev VN: Selenium and selenocysteine: roles in cancer, health, and development. Trends Biochem Sci 39, 112–120, 2014.
   PubMed Web of Science ®Google Scholar
• Luchman HA, Villemaire ML, Bismar TA, Carlson BA, and Jirik FR: Prostate epithelium-specific deletion of the selenocysteine tRNA gene Trsp leads to early onset intraepithelial neoplasia. Am J Pathol 184, 871–877, 2014.
   PubMed Web of Science ®Google Scholar
• Ganther HE: Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 20, 1657–1666, 1999.
   PubMed Web of Science ®Google Scholar
• Ip C and Ganther HE: Activity of methylated forms of selenium in cancer prevention. Cancer Res 50, 1206–1211, 1990.
   PubMed Web of Science ®Google Scholar
• Ip C, Hayes C, Budnick RM, and Ganther HE: Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 51, 595–600, 1991.
   PubMed Web of Science ®Google Scholar
• Ip C, Vadhanavikit S, and Ganther H: Cancer chemoprevention by aliphatic selenocyanates: effect of chain length on inhibition of mammary tumors and DMBA adducts. Carcinogenesis 16, 35–38, 1995.
   PubMed Web of Science ®Google Scholar
• Ip C, Zhu Z, Thompson HJ, Lisk D, and Ganther HE: Chemoprevention of mammary cancer with Se-allylselenocysteine and other selenoamino acids in the rat. Anticancer Res 19, 2875–2880, 1999.
   PubMed Web of Science ®Google Scholar
• Lu J, Jiang C, Kaeck M, Ganther H, Vadhanavikit S, et al.: Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 50, 213–219, 1995.
   PubMed Web of Science ®Google Scholar
• Lu J: Apoptosis and angiogenesis in cancer prevention by selenium. Adv Exp Med Biol 492, 131–145, 2001.
   PubMed Web of Science ®Google Scholar
• Zhao R, Xiang N, Domann FE, and Zhong W: Expression of p53 enhances selenite-induced superoxide production and apoptosis in human prostate cancer cells. Cancer Res 66, 2296–2304, 2006.
   PubMed Web of Science ®Google Scholar
• Hu H, Jiang C, Schuster T, Li GX, Daniel PT, et al.: Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol Cancer Ther 5, 1873–1882, 2006.
   PubMed Web of Science ®Google Scholar
• Lu J, Pei H, Ip C, Lisk DJ, Ganther H, et al.: Effect on an aqueous extract of selenium-enriched garlic on in vitro markers and in vivo efficacy in cancer prevention. Carcinogenesis 17, 1903–1907, 1996.
   PubMed Web of Science ®Google Scholar
• Kaeck M, Lu J, Strange R, Ip C, Ganther HE, et al.: Differential induction of growth arrest inducible genes by selenium compounds. Biochem Pharmacol 53, 921–926, 1997.
   PubMed Web of Science ®Google Scholar
• Jiang C, Wang Z, Ganther H, and Lu J: Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 1, 1059–1066, 2002.
   PubMed Web of Science ®Google Scholar
• Wang Z, Jiang C, Ganther H, and Lu J: Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling. Cancer Res 61, 7171–7178, 2001.
   PubMed Web of Science ®Google Scholar
• Wang Z, Jiang C, and Lu J: Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 34, 113–120, 2002.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Jiang W, Ganther HE, and Thompson HJ: Mechanisms of cell cycle arrest by methylseleninic acid. Cancer Res 62, 156–164, 2002.
   PubMed Web of Science ®Google Scholar
• Wang L, Hu H, Wang Z, Xiong H, Cheng Y, et al.: Methylseleninic acid suppresses pancreatic cancer growth involving multiple pathways. Nutr Cancer 66, 295–307, 2014.
   PubMed Web of Science ®Google Scholar
• Sinha R and Medina D: Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells. Carcinogenesis 18, 1541–1547, 1997.
   PubMed Web of Science ®Google Scholar
• Sinha R, Kiley SC, Lu JX, Thompson HJ, Moraes R, et al.: Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cells. Cancer Lett 146, 135–145, 1999.
   PubMed Web of Science ®Google Scholar
• Jiang C, Ganther H, and Lu J: Monomethyl selenium—specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog 29, 236–250, 2000.
   PubMed Web of Science ®Google Scholar
• Jiang C, Jiang W, Ip C, Ganther H, and Lu J: Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 26, 213–225, 1999.
   PubMed Web of Science ®Google Scholar
• Cho SD, Jiang C, Malewicz B, Dong Y, Young CY, et al.: Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 3, 605–611, 2004.
   PubMed Web of Science ®Google Scholar
• Dong Y, Lee SO, Zhang H, Marshall J, Gao AC, et al.: Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 64, 19–22, 2004.
   PubMed Web of Science ®Google Scholar
• Zhao H, Whitfield ML, Xu T, Botstein D, and Brooks JD: Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol Biol Cell 15, 506–519, 2004.
   PubMed Web of Science ®Google Scholar
• Lee SO, Nadiminty N, Wu XX, Lou W, Dong Y, et al.: Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res 65, 3487–3492, 2005.
   PubMed Web of Science ®Google Scholar
• Shah YM, Kaul A, Dong Y, Ip C, and Rowan BG: Attenuation of estrogen receptor alpha (ERalpha) signaling by selenium in breast cancer cells via downregulation of ERalpha gene expression. Breast Cancer Res Treat 92, 239–250, 2005.
   PubMed Web of Science ®Google Scholar
• Shah YM, Al-Dhaheri M, Dong Y, Ip C, Jones FE, et al.: Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells. Mol Cancer Ther 4, 1239–1249, 2005.
   PubMed Web of Science ®Google Scholar
• Cai L, Mu LN, Lu H, Lu QY, You NC, et al.: Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 15, 294–300, 2006.
   PubMed Web of Science ®Google Scholar
• Gao R, Zhao L, Liu X, Rowan BG, Wabitsch M, et al.: Methylseleninic acid is a novel suppressor of aromatase expression. J Endocrinol 212, 199–205, 2012.
   PubMed Web of Science ®Google Scholar
• Hu H, Li GX, Wang L, Watts J, Combs GF, Jr., et al.: Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. Clin Cancer Res 14, 1150–1158, 2008.
   PubMed Web of Science ®Google Scholar
• Guo X, Yin S, Dong Y, Fan L, Ye M, et al.: Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of Mcl-1 and FAK. Mol Carcinog 52, 879–889, 2013.
   PubMed Web of Science ®Google Scholar
• Yin S, Dong Y, Li J, Fan L, Wang L, et al.: Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad. Apoptosis 17, 388–399, 2012.
   PubMed Web of Science ®Google Scholar
• Gromer S and Gross JH: Methylseleninate is a substrate rather than an inhibitor of mammalian thioredoxin reductase: Implications for the antitumor effects of selenium. J Biol Chem 277, 9701–9706, 2002.
   PubMed Web of Science ®Google Scholar
• Gundimeda U, Schiffman JE, Chhabra D, Wong J, Wu A, et al.: Locally generated methylseleninic acid induces specific inactivation of protein kinase C isoenzymes: relevance to selenium-induced apoptosis in prostate cancer cells. J Biol Chem 283, 34519–34531, 2008.
   PubMed Web of Science ®Google Scholar
• Gundimeda U, Schiffman JE, Gottlieb SN, Roth BI, and Gopalakrishna R: Negation of the cancer-preventive actions of selenium by over-expression of protein kinase cepsilon and selenoprotein thioredoxin reductase. Carcinogenesis 30, 1553–1561, 2009.
   PubMed Web of Science ®Google Scholar
• Wu M, Kang MM, Schoene NW, and Cheng WH: Selenium compounds activate early barriers of tumorigenesis. J Biol Chem 285, 12055–12062, 2010.
   PubMed Web of Science ®Google Scholar
• Wu M, Wu RT, Wang TT, and Cheng WH: Role for p53 in selenium-induced senescence. J Agric Food Chem 59, 11882–11887, 2011.
   PubMed Web of Science ®Google Scholar
• Hagemann-Jensen M, Uhlenbrock F, Kehlet S, Andresen L, Gabel-Jensen C, et al.: The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D. J Biol Chem 289, 31576–31590, 2014.
   PubMed Web of Science ®Google Scholar
• Ip C, Thompson HJ, Zhu Z, and Ganther HE: In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60, 2882–2886, 2000.
   PubMed Web of Science ®Google Scholar
• Ip C and Hayes C: Tissue selenium levels in selenium-supplemented rats and their relevance in mammary cancer protection. Carcinogenesis 10, 921–925, 1989.
   PubMed Web of Science ®Google Scholar
• Qi Y, Fu X, Xiong Z, Zhang H, Hill SM, et al.: Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PLoS One 7, e31539, 2012.
   PubMed Web of Science ®Google Scholar
• Lindshield BL, Ford NA, Canene-Adams K, Diamond AM, Wallig MA, et al.: Selenium, but not lycopene or vitamin E, decreases growth of transplantable dunning R3327-H rat prostate tumors. PLoS One 5, e10423, 2010.
   PubMed Web of Science ®Google Scholar
• Christensen MJ, Quiner TE, Nakken HL, Lephart ED, Eggett DL, et al.: Combination effects of dietary soy and methylselenocysteine in a mouse model of prostate cancer. Prostate 73, 986–995, 2013.
   PubMed Web of Science ®Google Scholar
• Wang L, Guo X, Wang J, Jiang C, Bosland MC, et al.: Methylseleninic acid super-activates P53-senescence cancer progression barrier in prostate lesions of Pten-knockout mouse. Cancer Prev Res (Phila) 2015 Oct 28 [Epub ahead of print].
   Google Scholar
• Jiang W, Jiang C, Pei H, Wang L, Zhang J, et al.: In vivo molecular mediators of cancer growth suppression and apoptosis by selenium in mammary and prostate models: lack of involvement of gadd genes. Mol Cancer Ther 8, 682–691, 2009.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang L, Anderson LB, Witthuhn B, Xu Y, et al.: Proteomic profiling of potential molecular targets of methyl-selenium compounds in the transgenic adenocarcinoma of mouse prostate model. Cancer Prev Res (Phila) 3, 994–1006, 2010.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang L, Li G, Anderson LB, Xu Y, et al.: Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds. Nutr Cancer 63, 778–789, 2011.
   PubMed Web of Science ®Google Scholar
• Fairweather-Tait SJ, Collings R, and Hurst R: Selenium bioavailability: current knowledge and future research requirements. Am J Clin Nutr 91, 1484S–1491S, 2010.
   PubMed Web of Science ®Google Scholar
• Winkel L, Feldmann J, and Meharg AA: Quantitative and qualitative trapping of volatile methylated selenium species entrained through nitric acid. Environmental science & Technology 44, 382–387, 2010.
   PubMed Web of Science ®Google Scholar
• De Laeter JR, Bohlke JK, De Bievre P, Hidaka H, Peiser HS, et al.: Atomic weights of the elements: Review 2000 (IUPAC technical report). Pure and Applied Chemistry 75, 683–800, 2003.
   Web of Science ®Google Scholar
• Ogra Y and Anan Y: Selenometabolomics: Identification of selenometabolites and specification of their biological significance by complementary use of elemental and molecular mass spectrometry. Journal of Analytical Atomic Spectrometry 24, 1477–1488, 2009.
   Web of Science ®Google Scholar
• Pedrero Z and Madrid Y: Novel approaches for selenium speciation in foodstuffs and biological specimens: a review. Analytica chimica acta 634, 135–152, 2009.
   PubMed Web of Science ®Google Scholar
• Suzuki KT, Ohta Y, and Suzuki N: Availability and metabolism of (77)Se-methylseleninic acid compared simultaneously with those of three related selenocompounds. Toxicology and Applied Pharmacology 217, 51–62, 2006.
   PubMed Web of Science ®Google Scholar
• Suzuki KT, Tsuji Y, Ohta Y, and Suzuki N: Preferential organ distribution of methylselenol source Se-methylselenocysteine relative to methylseleninic acid. Toxicology and Applied Pharmacology 227, 76–83, 2008.
   PubMed Web of Science ®Google Scholar
• Ohta Y, Kobayashi Y, Konishi S, and Hirano S: Speciation analysis of selenium metabolites in urine and breath by HPLC- and GC-inductively coupled plasma-MS after administration of selenomethionine and methylselenocysteine to rats. Chemical Research in Toxicology 22, 1795–1801, 2009.
   PubMed Web of Science ®Google Scholar
• Johnson WD, Morrissey RL, Kapetanovic I, Crowell JA, and McCormick DL: Subchronic oral toxicity studies of Se-methylselenocysteine, an organoselenium compound for breast cancer prevention. Food Chem Toxicol 46, 1068–1078, 2008.
   PubMed Web of Science ®Google Scholar
• Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, et al.: Methyl selenocysteine: single-dose pharmacokinetics in men. Cancer Prev Res (Phila) 4, 1938–1944, 2011.
   PubMed Web of Science ®Google Scholar
• el-Bayoumy K, Upadhyaya P, Chae YH, Sohn OS, Rao CV, et al.: Chemoprevention of cancer by organoselenium compounds. J Cell Biochem 22(Suppl), 92–100, 1995.
   Google Scholar
• NCI Committee: Clinical development plan: 1,4-phenylenebis-(methylene)selenocyanate (p-XSC). NCI-DCPC Chemoprevention Branch and Agent Development Committee Report. Journal of Cellular Biochemistry 26S, 8, 1996.
   Google Scholar
• Conaway CC, Upadhyaya P, Meschter CL, Kurtzke C, Marcus LA, et al.: Subchronic toxicity of benzyl selenocyanate and 1,4-phenylenebis(methylene)selenocyanate in F344 rats. Fundam Appl Toxicol 19, 563–574, 1992.
   PubMedGoogle Scholar
• Sharma AK and Amin S: Post SELECT: selenium on trial. Future Med Chem 5, 163–174, 2013.
   PubMed Web of Science ®Google Scholar
• Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, et al.: Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J Med Chem 51, 7820–7826, 2008.
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, et al.: Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res 15, 1674–1685, 2009.
   PubMed Web of Science ®Google Scholar
• Crampsie MA, Pandey MK, Desai D, Spallholz J, Amin S, et al.: Phenylalkyl isoselenocyanates vs phenylalkyl isothiocyanates: thiol reactivity and its implications. Chem Biol Interact 200, 28–37, 2012.
   PubMed Web of Science ®Google Scholar
• Sharma AK, Sk UH, He P, Peters JM, and Amin S: Synthesis of isosteric selenium analog of the PPARbeta/delta agonist GW501516 and comparison of biological activity. Bioorg Med Chem Lett 20, 4050–4052, 2010.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Sk UH, Zhang Y, Ren X, Zhang L, et al.: Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death. PLoS One 7, e35104, 2012.
   PubMed Web of Science ®Google Scholar
• Misra S, Boylan M, Selvam A, Spallholz JE, and Bjornstedt M: Redox-active selenium compounds—from toxicity and cell death to cancer treatment. Nutrients 7, 3536–3556, 2015.
   PubMed Web of Science ®Google Scholar